Please assess the completion status of the following clinical trial:

Trial Title: Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* o At least 18 years of age~  * Male or female patient who had DMEK within the past 1 to 7 weeks.~ * Patient is able and willing to administer eye drops.~ * Patient is able to comprehend and has signed the Informed Consent form.~ * Patient is likely to complete the 11-month study duration.~Exclusion Criteria:~* o A history of a previous rejection episode in the study eye~  * A patient exhibiting intraocular inflammation.~ * A patient with a known sensitivity to any of the ingredients in the study medications~ * A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study~ * A patient with abnormal eyelid function.~ * A patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis.~ * Presence of any ocular disease that would interfere with the evaluation of the study treatment. However, patients with a history of cystoid macular edema, age-related macular degeneration, controlled glaucoma, corneal neovascularization, and other non-interfering comorbidities may be enrolled.~ * A patient with a history of non-compliance with using prescribed medication.~ * Patients who are pregnant or planning to become pregnant within the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preventative Treatment (Type: EXPERIMENTAL): Loteprednol etabonate ophthalmic suspension 0.25% dosed 4 times daily for 2 months, 3 times daily for one month, twice daily for one month, and once daily until the 1 year postop exam.

Based on this trial design, predict the completion outcome and termination type (if applicable).